Effect of L-Acetylcarnitine on Body Composition in HIV-related Lipodystrophy

Abstract

This study examined the impact of L-acetylcarnitine treatment on metabolic parameters and body composition in patients with lipodystrophy syndrome secondary to antiretroviral treatment in human immunodeficiency virus (HIV) infection. A total of 9 HIV-1 infected patients with lipodystrophy syndrome (4F/5M, age 41±5 years, HIV duration 8±2 years, BMI 23.7±3.4 kg/m², on protease inhibitors and nucleoside analogue Reverse Transcriptase inhibitors) were evaluated before and after 8 months of therapy with L-acetylcarnitine (2 g/die) and 9 matched healthy subjects served as control subjects. In all patients fasting plasma glucose, insulin concentrations (for evaluation of surrogate indexes of insulin sensitivity), lipid profile, lipid oxidation (by indirect calorimetry), body composition (by DEXA), and intramyocellular triglyceride (IMCL) content of the calf muscles (by ¹ H NMR spectroscopy) were assessed. After this therapy, in HIV-1 patients, the IMCL content of the soleus had significantly decreased (p=0.03). Plasma FFAs (0.79±0.31 to 0.64±0.25; p<0.05) and Respiratory Quotient (0.83±0.18 to 0.72±0.16; p<0.03) also decreased. Insulin sensitivity was significantly lower prior (HOMA-IS 0.56±0.30) and nonstatistically different than controls after therapy (0.72±0.49 vs. 0.78±0.42) whilst the percentage of fat in the legs increased (p=0.05). Eight months of L-acetylcarnitine treatment increased lipid oxidation, decreased intramyocellular triglyceride content, and induced a more physiological distribution of fat deposits.

Key words

energy metabolism - human immunodeficiency virus - NMR spectroscopy - insulin sensitivity

References

• 1 Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.  AIDS. 1998;  12 F51-F58
• 2 Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, Rouviere O, Lang JM, Gastaut JA, Touraine JL. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.  AIDS. 1999;  13 1659-1667
• 3 Capiluppi B, Ciuffreda D, Sciandra M, Marroni M, Tambussi G, Lazzarin A. Metabolic disorders in a cohort of patients treated with highly aggressive antiretroviral therapies during primary HIV-1 infection.  AIDS. 2000;  14 1861-1862
• 4 Luzi L, Perseghin G, Tambussi G, Meneghini E, Scifo P, Pagliato E, Del Maschio A, Testolin G, Lazzarin A. Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy.  Am J Physiol Endocrinol Metab. 2003;  284 E274-E280
• 5 Nolan D. Metabolic complications associated with HIV protease inhibitor therapy.  Drugs. 2003;  63 2555-2574
• 6 Renard E, Fabre J, Paris F, Reynes J, Bringer J. Syndrome of body fat redistribution in HIV-1-infected patients: relationships to cortisol and catecholamines.  Clin Endocrinol (Oxf). 1999;  51 223-230
• 7 Rietschel P, Hadigan C, Corcoran C, Stanley T, Neubauer G, Gertner J, Grinspoon S. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy.  J Clin Endocrinol Metab. 2001;  86 504-510
• 8 Jorgensen JO, Krag M, Kanaley J, Moller J, Hansen TK, Moller N, Christiansen JS, Orskov H. Exercise, hormones, and body temperature regulation and action of GH during exercise.  J Endocrinol Invest. 2003;  26 838-842
• 9 Murray RD, Adams JE, Shalet SM. Adults with partial growth hormone deficiency have an adverse body composition.  J Clin Endocrinol Metab. 2004;  89 1586-1591
• 10 Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus . Diabetes Care. 1998;  21 ((Suppl 1)) S5-S19
• 11 Polo M, Galli M, Scientmark T, Walli R. Proposal for a clinical and metabolic classification of metabolic and hormone abnormalities under HAART. In: Int Workshop 2nd on HIV-related Lipodystrophy. Marrakesh, Morocco 2000
• 12 Luzi L, Castellino P, DeFronzo RA. Insulin and hyperaminoacidemia regulate by a different mechanism leucine turnover and oxidation in obesity.  Am J Physiol Endocrinol Metab. 1996;  270 E273-E281
• 13 Perseghin G, Scifo P, De Cobelli F, Pagliato E, Battezzati A, Arcelloni C, Vanzulli A, Testolin G, Pozza G, Del Maschio A, Luzi L. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents.  Diabetes. 1999;  48 1600-1606
• 14 Perseghin G, Scifo P, Danna M, Battezzati A, Benedini S, Meneghini E, Del Maschio A, Luzi L. Normal insulin sensitivity and IMCL content in overweight humans are associated with higher fasting lipid oxidation.  Am J Physiol Endocrinol Metab. 2002;  283 E556-E564
• 15 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419
• 16 Perseghin G, Caumo A, Piceni Sereni L, Battezzati A, Luzi L. Fasting blood sample-based assessment of insulin sensitivity in kidney-pancreas-transplanted patients.  Diabetes Care. 2002;  25 2207-2211
• 17 Perseghin G, Caumo A, Caloni M, Testolin G, Luzi L. Incorporation of the fasting plasma FFA concentration into QUICKI improves its association with insulin sensitivity in nonobese individuals.  J Clin Endocrinol Metab. 2001;  86 4776-4781
• 18 van der Valk M, Allick G, Weverling GJ, Romijn JA, Ackermans MT, Lange JM, van Eck-Smit BL, van Kuijk C, Endert E, Sauerwein HP, Reiss P. Markedly diminished lipolysis and partial restoration of glucose metabolism, without changes in fat distribution after extended discontinuation of protease inhibitors in severe lipodystrophic human immunodeficient virus-1-infected patients.  J Clin Endocrinol Metab. 2004;  89 3554-3560
• 19 Haugaard SB, Andersen O, Dela F, Holst JJ, Storgaard H, Fenger M, Iversen J, Madsbad S. Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic beta-cells.  Eur J Endocrinol. 2005;  152 103-112
• 20 Wutzke KD, Lorenz H. The effect of L-carnitine on fat oxidation, protein turnover, and body composition in slightly overweight subjects.  Metabolism. 2004;  53 1002-1006
• 21 Mingrone G, Greco AV, Capristo E, Benedetti G, Giancaterini A, De Gaetano A, Gasbarrini G. L-Carnitine improves glucose disposal in type 2 diabetic patients.  J Am Coll Nutr. 1999;  18 77-82
• 22 Reynier M, Brun JF, Orsetti A. Metabolic effects of L-carnitine, L-lysine methionine during maximal exercise.  Sci Sport. 1996;  13 17-25
• 23 De Gaetano A, Mingrone G, Castagneto M, Calvani M. Carnitine increases glucose disposal in humans.  J Am Coll Nutr. 1999;  18 289-295
• 24 Luzi L, Meneghini E, Oggionni S, Tambussi G, Piceni-Sereni L, Lazzarin A. GH treatment reduces trunkal adiposity in HIV-infected patients with lipodystrophy: a randomized placebo-controlled study.  Eur J Endocrinol. 2005;  153 781-789
• 25 Bujalska IJ, Kumar S, Hewison M, Stewart PM. Differentiation of adipose stromal cells: the roles of glucocorticoids and 11β-hydroxysteroid dehydrogenase.  Endocrinology. 1999;  140 3188-3196
• 26 Tomlinson JW, Sinha B, Bujalska I, Hewison M, Stewart PM. Expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity.  J Clin Endocrinol Metab. 2002;  87 5630-5563
• 27 He Q, Engelson ES, Albu JB, Heymsfield SB, Kotler DP. Preferential loss of omental-mesenteric fat during growth hormone therapy of HIV-associated lipodystrophy.  J Appl Physiol. 2003;  94 2051-2057
• 28 Kotler DP, Muurahainen N, Grunfeld C, Wanke C, Thompson M, Saag M, Bock D, Simons G, Gertner JM. Serostim in Adipose Redistribution Syndrome Study Group. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients.  J Acquir Immune Defic Syndr. 2004;  35 239-252
• 29 Sutinen J, Kannisto K, Korsheninnikova E, Nyman T, Ehrenborg E, Andrew R, Wake DJ, Hamsten A, Walker BR, Yki-Järvinen H. In the lipodystrophy associated with highly active antiretroviral therapy, pseudo-Cushing's syndrome is associated with increased regeneration of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue.  Diabetologia. 2004;  47 1668-1671
• 30 Buyse J, Janssens GP, Decuypere E. The effects of dietary L-carnitine supplementation on the performance, organ weights and circulating hormone and metabolite concentrations of broiler chickens reared under a normal or low temperature schedule.  Br Poult Sci. 2001;  42 230-241
• 31 Kraemer WJ, Volek JS, French DN, Rubin MR, Sharman MJ, Gòmes AL, Ratamess NA, Newton RU, Jemiolo B, Craig BW, Hakkinen K. The effects of amino acid supplementation on muscular performance during resistance training overreaching.  J Strength Cond Res. 2003;  17 250-258
• 32 Parr TB. A new technique to elevate night time growth hormone release and a potential growth hormone feedback control loop.  Med Hypotheses. 2001;  56 610-613
• 33 Di Marzio L, Moretti S, D’Alòa S, Zazzeronia F, Marcellini S, Smacchia C, Alesse E, Cifone MC, De Simone C. Acetyl-L-carnitine administration increases insulin-like growth factor 1 levels in asymptomatic HIV-1-infected subjects: correlation with its suppressive effect on lymphocyte apoptosis and ceramide generation.  Clin Immunol. 1999;  92 103-110
• 34 Benedini S, Terruzzi I, Lazzarin A, Luzi L. Recombinant Human Growth hormone for the Treatment of HIV-Associated Adipose Redistribution Syndrome.  BioDrugs. 2008;  22 101-112
• 35 Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Metabolic effects of a growth hormone-releasing factor in patients with HIV.  N Engl J Med. 2007;  357 2359-2370
• 36 Lo J, You SM, Canavan B, Liebau J, Beltrani G, Koutkia P, Hemphill L, Lee H, Grinspoon S. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial.  JAMA. 2008;  300 509-519

Correspondence